Hazard identification is the first step in assessing the risk of a genetically modified (GM) crop. It employs the concept of substantial equivalence to evaluate crop safety. The current process relies on subjective opinions to integrate various comparisons among the GM crop, the non-GM counterpart and an assortment of non-GM references over an array of key endpoints measured in field trials. The pre-eminent need to control the consumer's risk in hazard identification has been left unaddressed. The current paper develops statistical strategies to resolve this issue. Hypotheses of individual tests are explicitly defined to reflect the study objectives. They are then grouped into families and connected by logical operators according to decision rules commonly used in crop safety evaluation. This pre-specification of hypotheses arranged in an organized layout leads to a simple, transparent decision-making process where the consumer's risk can be managed directly. A two-stage multiplicity adjustment procedure is created by applying fundamental principles for multiple testing to the newly assembled families of hypotheses. The practical utility of the proposed procedure is shown in a real-world example. Besides being easy to implement and convey, the proposed statistical strategies accommodate the addition of supportive evidence for safety and allow the nature of the genetic modification to be taken into account.
INTRODUCTION
The risk assessment of a genetically modified (GM) crop and the derived products for food and animal feed begins with hazard identification, which is facilitated by evaluating the safety of samples collected from a multi-site field study (König et al. 2004; EFSA 2010) . The concept of substantial equivalence is the principal guidance for this safety evaluation (OECD 1993; Codex Alimentarius Commission 2009) . It assesses safety with respect to key agronomic, phenotypic and compositional characteristics specific to the crop species. For a given endpoint, equivalence is established if the genetically modified organism (GMO) gives values similar to the non-GM isogenic/ near-isogenic comparator or within the natural variation of non-GM reference crops with a history of safe use. Endpoints with uncertain equivalence are subjected to hazard characterization that involves animal testing of the whole food (EFSA 2008 (EFSA , 2014 and exposure assessment.
The multi-site study of crop safety typically plants GMO, the non-GM counterpart and several references together at each site according to a randomized block design. Suppose 
Retaining H m TC is taken as no difference and therefore equivalent. Only endpoints with rejected H m TC are evaluated further, in a post hoc manner, under the context of biological relevance and natural variation of non-GM crops. Table 1 cites several sponsors' strategies for exempting endpoints from hazard characterization and exposure assessment. Note that some sponsors adjusted P values for testing hypotheses (1) by controlling the false discovery rate (FDR) (Benjamini & Hochberg 1995) . As indicated by the flow chart of this process ( Fig. 1) , conclusions of safety were based on either non-significant results or various subjective explanations.
The European Food and Safety Authority (EFSA) mandates a procedure that entails two types of comparisons (EFSA 2010) . The first type compares GMO with the non-GM counterpart. It is formulated as hypotheses (1) except that parameters here pertain to the mixed model for natural-log-transformed data. The EFSA recommends a log transformation for data measured on a continuous scale because (1) many biological effects are multiplicative rather than additive; (2) transformed data tends to become homoscedastic; (3) normality seems to be better achieved upon transforming the compositional data. Statistical testing is set at the 0·10 significance level for each endpoint. The EFSA considers FDR adjustment to difference tests insufficient for GMO risk assessment. Instead, re-sampling is used to determine how likely it is to attain the observed number of endpoints with a significant difference under the assumption that μ m T À μ m C has a zero-mean normal distribution. The second type compares GMO with references grown Table 1 . Traditional strategies to exclude GMO endpoints from hazard characterization and exposure assessment Publication (sponsor) Multiplicity adjustment* Post hoc explanation Berman et al. 2010 (Monsanto) No . The percent change of GMO relative to its non-GM counterpart was small;
. The observed mean of GMO was contained by the tolerance interval estimated from in-study references Herman et al. 2013 (Dow AgroSciences) Yes . The percent change of GMO relative to its non-GM counterpart was small;
. Site means of GMO were comparable with those of in-study references Lepping et al. 2013 (Dow AgroSciences) Yes . The percent change of GMO relative to its non-GM counterpart was small;
. The study was overpowered for the difference test;
. Values of GMO were within the data range of in-study references Lundry et al. 2013 (Monsanto) No . The percent change of GMO relative to its non-GM counterpart was small;
. The data range of GMO overlapped with that of the non-GM counterpart; . Values of GMO reflected the variability observed from the tolerance interval of in-study references and the literature range of historical references Brink et al. 2014 (DuPont Pioneer) Yes . The percent change of GMO relative to its non-GM counterpart was small;
concurrently in the study. Let μ m R be the reference mean. The guidance tests equivalence, i.e. 
whereÊL is the equivalence limit (EL) estimated from the observed natural variation of in-study references. The guidance suggests applying FDR-controlling procedures to adjust equivalence tests across endpoints, but leaves this option open for future improvement. By the two one-sided tests (TOST) of Schuirmann (1987) , the null in hypotheses (2) or (3) R with ðÀÊL;ÊLÞ leads to the conclusion of 'equivalence more likely than not' or 'non-equivalence more likely than not'. The flow chart of this process (Fig. 2) indicates a series of issues in EFSA's comparative analysis. Ignoring the uncertainty in estimatingÊL makes the actual type I error rate intractable (Kang & Vahl 2014) . Testing for non-equivalence contributes little in deciding whether to evaluate further, since EFSA requests more investigation as either a must or a maybe for endpoints lacking the conclusion of equivalence. The assertion of 'more likely than not', when both nulls are retained, makes sense only when one considers parameters to be random quantities with a posterior probability distribution. It is a Bayesian interpretation and does not belong to the realm of frequentist inference. Moreover, using both 0·10 and 0·05 significance levels in the same study is unconventional and difficult to defend. For endpoints with retained nulls of hypotheses (2) and (3), EFSA encourages sponsors to incorporate results of the two types of comparisons when deciding whether to proceed with hazard characterization and exposure assessment. Yet there has been no detailed instruction on how to interpret these results. In July 2015, nine non-government organizations requested the European Commission to review the authorization for the import of a GM oilseed rape. Uncertainty in the statistical analysis was one of the filed complaints (EFSA 2015a).
The safety evaluation of a GM crop is inherently a decision-making process with a confirmatory nature. Multiple testing procedures (MTPs) strive to assure that results concluded from a single study are replicable. Often this is achieved by strongly controlling the familywise error rate (FWER), i.e. limiting the maximum probability of making at least one wrong inference under any configuration of nulls. Properly stating hypotheses according to the study objective constitutes an intrinsic, crucial element in creating MTPs. When hypotheses (1) are used to establish substantial equivalence, the corresponding multiplicity adjustment controls the probability of wrongfully concluding that the genetic engineering has changed the crop in at least one endpoint. This error rate corresponds to the sponsor's risk. However, the more important error to control is the consumer's risk, i.e. the probability of erroneously asserting equivalence on one or more potentially hazardous endpoints. Adjusting for multiplicity in testing hypotheses (1) is a mismatch for the study objectives. Although a strong FWER control is indispensable for studies at the confirmatory stage, many practitioners consider it counterproductive in exploratory research. The FDR, on the other hand, is an alternative error rate definition that has gained popularity in analysing highdimensional data generated by high-throughput technologies. It refers to the expected proportion of false rejections among all rejected nulls. Adjustment of FDR has attracted attention from both the ag-biotech Fig. 1 . Flow chart for the traditional process that focuses on the difference test. This process compares genetically modified organisms (GMO) to non-GM crops in a post hoc manner using various subjective explanations. industry and EFSA, albeit for controlling different types of risk. Note that FDR-controlling MTPs attain better power at the expense of the FWER. Finner & Roters (2001) further reveal that the FDR is susceptible to 'cheating' by adding irrelevant hypotheses with almost sure rejection. Hence, regulatory guidance on confirmatory clinical trials requests control of the FWER (CPMP 2002; FDA 2009 ; also see Hsu 2010 for a succinct introduction on this topic). Provided hypotheses for crop safety evaluation are well formulated, a strong control on the FWER is capable of restricting the consumer's risk in the worst-case scenario and better addresses the public's rising concerns on food safety. Hence, FDR-controlling procedures ought to be avoided in establishing substantial equivalence.
Two sources of multiplicity exist in GMO testing from field trials. One obvious source comes from the many endpoints under evaluation. The other, which has not received much attention, arises from the comparisons of GMO v. the non-GM counterpart and again v. the references. Previous evaluations have mishandled the latter source with a barrage of post hoc explanations. There is certainly ample opportunity to strengthen the scientific integrity of this process. Simple, off-the-shelf MTPs are, nonetheless, inadequate to handle this complex multiplicity problem. A general strategy for creating MTPs has been outlined in the context of clinical trials (Chi 1998; Dmitrienko et al. 2003; Chen et al. 2005; Hung & Wang 2009 , 2010 . There, the sponsor converts the overall objective of the study into a list of explicit claims and organizes them as a set of decision rules. The statistician translates these claims and decision rules into hypotheses interlinked by logical operators. An MTP is then created to suit the specific layout of these hypotheses. Given the observed data, the decision-making process is solely driven by the multiplicity-adjusted statistical results. Specification of the MTP upfront without any post hoc alterations is thus critically important for preserving the FWER. Strategic planning of the MTP not only motivates a process with logical flow but also reduces conservativeness in multiplicity adjustment. Many customized MTPs have been created for various clinical studies with several sources of multiplicity (a comprehensive review is available in . These studies all entail efficacy assessment whose objectives and decision rules differ fundamentally from safety evaluation. Statistical methods have also been developed for exploratory analyses of drug adverse events obtained from clinical efficacy trials and post-marketing spontaneous reports (Berry & Berry 2004; Mehrotra & Heyse 2004; Gould 2008; Huang et al. 2011) . These types of safety assessment avoid formal hypothesis testing and FWER control. A new MTP is needed particularly for establishing GMO substantial equivalence based on endpoints measured from crop field trials. The current paper aims to develop statistical strategies for adjusting multiplicity in the safety evaluation of a GM crop. For each comparison at every endpoint, individual hypotheses are explicitly defined to mirror the study objectives. Guided by the decision rules currently in use, these hypotheses are grouped into families and linked by logical operators to form composite hypotheses. This objective testing of pre-specified hypotheses arranged in an organized layout results in a transparent evaluation process where the consumer's risk can be directly controlled. A twostage MTP tailored specifically to the unique hypothesis layout is then created by applying fundamental principles for multiple testing. The newly proposed MTP is simple to implement and communicate. Its utility is shown in a real-world example, dismissing the concern that a statistical conclusion of safety is hopelessly unattainable via multiple equivalence testing. Finally, the proposed MTP is discussed in regard to its potential improvements and additional generalizations.
MATERIALS AND METHODS

Formulating individual hypotheses
The logic of hypothesis testing places the target assertion into the alternative hypothesis. Everything else within the parameter space of interest goes into the null. The sponsor of an efficacy study supports its product's regulatory approval by rejecting the null of zero-difference. The sponsor of a safety study should firmly defend its product's authorization by rejecting the null of non-equivalence, rather than blindly adopting the hypotheses in the efficacy study and wishing for non-significance. Defining safety in terms of equivalence is not without precedence. For example, Hsu & Berger (1999) advocate tests of practical equivalence in assessing the toxicity of bovine growth hormone. Oberdoerfer et al. (2005) were the first to apply equivalence testing to crop safety evaluation. Practitioners, on the other hand, are often attracted by the mathematical convenience in testing for difference and avoid equivalence testing due to complications in defining appropriate ELs. Blunt advice against reliance on such ill-posed hypotheses is to cite Hsu (1996) : 'an approximate solution to the right problem … will be better than an exact solution to the wrong problem, the latter accounting for a significant portion of the abuse.' Table 1 shows a consensus that μ m T À μ m C must be small to establish equivalence. The present work proposes to compare GMO with the non-GM counterpart at endpoint m by testing
Value δ 0 defines a 'zone of indifference' where differences inside it are considered trivial for practical purposes. It establishes similarity, or practical equivalence, but has no direct implications on safety. Because μ m T and μ m C are parameters in the mixed model analysis of the log-transformed data, [exp (δ 0 ) − 1] represents the largest tolerated change of GMO relative to the non-GM counterpart in terms of their back-transformed, i.e. geometric, means. The EFSA guidance used 'percent change (e.g. −20% and +25%) for relatively small changes, or factors (e.g. ½ and 2) for larger changes' whereas Oberdoerfer et al. (2005) used ±20%. A working δ 0 could then be set as ln(1.25) or ln(1.20). Hypotheses (4) cannot be used as the sole component for establishing equivalence at a given endpoint, because it does not incorporate crop's natural variation. Hothorn & Oberdoerfer (2006) explored several options for defining endpoint-specific ELs. Unfortunately, these definitions fall short in biological validity or statistical rigour.
The current paper addresses natural variation through additional hypotheses that compare GMO with references. As mentioned earlier, crop safety studies employ the multi-site design where various references and GMO are randomized into plots arranged in blocks at each site. Under the linear mixed model of EFSA, natural variation can be easily incorporated into the EL. introduced the following hypotheses to assess the equivalence of GMO to references at endpoint m. 
The EFSA guidance also tests non-equivalence, whose hypotheses reverse the null and alternative of the equivalence test. While an improvement over a simple test of zero-difference, this test of non-equivalence is still a mismatch with the proof-of-safety objective. It represents the subconscious reversion to traditional exploratory toxicity studies with a proofof-hazard purpose (Hothorn & Hasler 2008) . Note that Δðδ; σ m Þ is not an exact rigid threshold for toxicity but rather a conservative soft limit of safety. Nonsignificant evidence for equivalence logically suggests further evaluation, whereas a conclusion of non-equivalence invites misinterpretation as established true hazard. Moreover, simultaneously testing two opposing objectives (hazard and safety) complicates the statistical decision-making process and hinders straightforward characterization of the consumer's risk. For these reasons, non-equivalence tests should be omitted in crop safety evaluation.
In a three-arm non-inferiority study of drug efficacy, non-inferiority of the test treatment to the active control relies on the assay sensitivity, which can be validated by testing the superiority of the active control over the placebo (Röhmel & Pigeot 2010 and the literature cited therein). This is founded on the concern that the active control may not be efficacious in the current study. A similar question is whether to compare GMO with references if the non-GM counterpart is not significantly equivalent to references under the same criterion. Unlike the active control and placebo in drug efficacy studies, both the non-GM counterpart and references are safe, a priori. It is unnecessary to test the non-GM counterpart against references and this question is moot.
Grouping hypotheses into families Tamhane (1996) defines a family as a set of comparisons from which some common conclusions are drawn and states that comparisons within this family must be contextually related but not necessarily statistically dependent. Grouping of individual hypotheses into relevant families should match the study objective and decision rule. Recall that M endpoints are subjected to mixed model analyses. There are 2M individual hypotheses and as many as 2 2M − 2M − 1 combinations to form composite hypotheses. One possible approach is to place comparisons involving the non-GM counterpart into one family, i.e. fH Table 1; EFSA 2015a EFSA , b, c, 2016 . This supports grouping the two comparisons at a given endpoint into a family, i.e. fH Members of a family can be linked by either intersection or union, which gives rise to two basic types of composite hypotheses: intersection-union (IU) and union-intersection (UI). The IU hypotheses place the intersection of individual alternatives in its alternative and the union of individual nulls in its null. It corresponds to an 'each-and-every' type of conclusion. In contrast, the UI hypotheses contain the union of individual alternatives in its alternative and the intersection of individual nulls in its null. It corresponds to an 'at-least-one' type of conclusion. Recall that GMO is regarded as safe if it is comparable with either the non-GM counterpart or references. Equivalence at a given endpoint shall then be formulated as the following local UI hypotheses.
To those who presume hypotheses (5) as a relaxation of hypotheses (4) Fig. 3(d) displays the situation of an overly conservative EL. In such a case, hypotheses (5) alone do not adequately represent the concept of substantial equivalence. Testing hypotheses (6) yields a reasonable solution. Tolerance intervals or literature ranges derived from non-GM crops are random quantities with intractable uncertainty. Because their usage is less transparent and prone to manipulation, the present work excludes them from the decision-making process. Figure 4 presents the flow chart for the proposed evaluation. Here the two partial decisions at endpoint m are integrated into a joint decision of overall equivalence by testing the local UI hypotheses. This supports a decisionmaking process on the basis of pre-specified justification rather than post hoc arguments. It is clearly an improvement over those processes in Figs 1 and 2.
Testing hypotheses (6) across M endpoints pertains to a new family of hypotheses. Figure 5 visualizes the organized layout at M = 3. Here the individual hypotheses are grouped into endpoint-specific families of hypotheses, whose UI composites then form a general family. Now the question is how to link members in this general family. Because equivalence at every endpoint implies global equivalence, one might consider the following global IU hypotheses.
Rejecting the null of hypotheses (7) would be a big win for the sponsor. But failing to do so does not result in an automatic regulatory denial, as hazard characterization and exposure assessment will be undertaken for endpoints that cause the null to be retained. Hypotheses (7) do not allow for endpointspecific conclusions and are therefore a mismatch for crop safety evaluation. Moreover, the type I error in testing hypotheses (7) refers to the assertion of global equivalence when non-equivalence occurs in some endpoints. Its probability does not correspond to the consumer's risk in hazard identification, i.e. the probability of erroneously asserting equivalence on one or more non-equivalent endpoints. According to the theoretical findings of Sonnemann & Finner (1988) , strong control on the error of rejecting at least one true H m can be achieved by adding the following UI composite hypotheses to the general family (see Fig. 5 ) and testing each H m via the well-established closure principle (a brief introduction on this principle is available in Appendix 1).
The index set I here is a subset of {1, …, M}. For M = 3, I = {1, 2}, {1, 3}, {2, 3}, {1, 2, 3}. Linking K m by '∪' may be difficult for some to comprehend, as these hypotheses are themselves of little practical interest. Nonetheless, expanding the general family to include UI hypotheses allows strong FWER control without compromising the power. In other words, testing such an expanded family of hypotheses is as good as testing the family with individual hypotheses only. It is worthwhile to mention that similar UI formulation of composite hypotheses is becoming increasingly common in multiendpoint bioequivalence and non-inferiority studies of drugs (Quan et al. 2001; Logan & Tamhane 2008; Hasler & Hothorn 2013; Hua et al. 2015) . This stems from the need for inference on individual endpoints. The multiple endpoints in drug safety evaluation, i.e. types of adverse events, can be categorized into several body systems on the basis of prior clinical understanding. Such grouping has been used to reduce false positive findings (Berry & Berry 2004; Mehrotra & Heyse 2004) . However, the intertwining relationship of plant metabolic pathways prevents any grouping of endpoints measured in crop safety evaluation. Consequently, there is no intermediate grouping of hypotheses (6) into subfamilies. Only the family containing hypotheses (6) across all endpoints is relevant for GMO testing.
A multiple testing procedure for genetically modified organism safety evaluation There are three fundamental principles governing multiple testing in the UI context. The closure principle establishes the general method for MTP construction. The sequential rejection principle and the partition principle exploit the relationships among individual hypotheses to improve power. A brief tutorial of these principles and their applications is given in Appendix 1. As mentioned previously, hypotheses (4) and (5) at a given endpoint are not nested. Neither sponsors nor regulatory agencies have articulated any decision path among endpoints measured in crop safety evaluation. This prevents hypotheses (6) from being arranged, in advance, into a fixed sequence. Sequential testing in a data-driven order is therefore the best available approach here. Practitioners accustomed to the analysis of variance setting may be familiar with Dunnett's parametric stepwise procedures used in comparing several treatments with a control (Dunnett & Tamhane 1991 , 1992 . Construction of these MTPs relies on the knowledge that the individual test statistics have a joint multivariate t distribution. The distinct formulation of hypotheses (4) and (5) makes it difficult to characterize such a joint distribution. The Simes-Hochberg (SH) procedure is a classical semiparametric sequential MTP (Westfall et al. 1999; . It circumvents the derivation of any joint distribution and is readily applicable to GMO testing. Appendix 1 provides the generic formula for the SH adjustment. Multiplicity adjustment can be carried out by either raising the P values or dropping the significance levels of individual tests. Because these two approaches yield identical conclusions, only the P-value-based approach is presented.
To accommodate the hypothesis layout in Fig. 5 , the present work proposes a two-stage MTP that executes the SH adjustment in both stages. The first stage derives the raw P value for testing hypotheses (6) at each endpoint. Suppose that the ordered P values for testing hypotheses (4) and (5) . According to the SH adjustment, the raw P value for testing hypotheses (6) is:
Let P ðmÞ be the m th smallest P value of fP 1 ; :::; P M g, i.e. P
. . . P ðMÞ . The second stage controls the consumer's risk by correcting for multiplicity across endpoints. The SH method is applied for a second time and P values for hypotheses (6) are adjusted sequentially as:
To preclude logical incoherence, this present work applies the closure principle and readjusts P values for individual hypotheses as: 
This assures that at a given endpoint, the P value for testing hypotheses (6) will be no greater than either of the two for testing hypotheses (4) and (5). Consequently, if the null of hypotheses (6) is retained, the corresponding nulls of hypotheses (4) and (5) are both retained.
The SH procedure has been demonstrated to strongly control the FWER for a general class of positively correlated multivariate distributions, many of which are encountered in multiple testing situations (Sarkar & Chang 1997; Sarkar 1998 Sarkar , 2008 . Excessive 'handwringing' on its analytical conditions is counterproductive in practice. Biological rationale for the positive relationship among multiple inferences should alleviate any concern on its validity here. In particular, proper selection of GMO comparators, as articulated by EFSA (2011), assures μ m C to be fairly close to μ m R . Results of the two within-endpoint comparisons are therefore expected to be positively correlated. Owing to the intricacy of plant system biology, a positive relationship is also expected from results of equivalence testing across endpoints. It is therefore anticipated that the proposed MTP will restrain the FWER effectively. The large number of hypotheses tested (2M >100) obstructs non-parametric adjustments carried out either by the single-step Bonferroni (SSB) procedure or the sequential Bonferroni-Holm (BH) procedure. A similar viewpoint has been expressed by Hothorn & Oberdoerfer (2006) , who employed the SH procedure in their multiple testing of hypotheses (4) across compositional endpoints. For side-by-side comparisons of these procedures for a single family of hypotheses, see the corresponding formulas in Appendix 1. Let α be the desired FWER. The benefit of the proposed MTP is best seen when P 1 , …,P M are all less than α. In this case, some of SSB-or BH-adjusted P values might be greater than α, which seems counterintuitive. The SHadjusted P values, on the other hand, would always remain less than α. Such consistency among outcomes was recognized by as a desirable property. It has served as an incentive for Quan et al. (2001) and Hasler & Hothorn (2013) to apply the SH adjustment in clinical equivalence and non-inferiority studies.
RESULTS
This section illustrates the newly developed MTP using a real-world dataset containing 53 compositional endpoints measured in a safety study on a GM maize. The EFSA guidance supplies the estimated μ , their corresponding standard errors, the approximated degrees of freedom, and estimated variance components in the mixed model. These summary statistics are sufficient to test hypotheses (4) and (5). Suppose that GMO is comparable with the non-GM counterpart if the ratio of their geometric means is between 0·833 and 1·20. To account for natural variation, assume that 2·5 th and 97·5 th percentiles of the reference distribution at the site and block level are the ELs for the GMO geometric mean. (4) were computed via the method of Anderson & Hauck (1983) . Appendix 2 exhibits their calculation using SAS (SAS Institute Inc 2011).
The P values for testing hypotheses (5) were obtained by running the SAS program given in . First, consider the simple case where crop safety was evaluated with respect to three analytes in the example dataset, namely, niacin, phytic acid and raffinose. Table 2 demonstrates how to manually implement the proposed two-stage MTP using the analytes' raw P values for testing hypotheses (4) and (5). Note that stage two of this MTP utilized the ranking of analytes' raw P values for testing Hypo (6) and made adjustments sequentially in the order of niacin, phytic acid and raffinose. Also note that the adjusted P value for testing hypotheses (5) of phytic acid (0·0418) was not a multiplier of its raw P value of 0·0196 but was borrowed from testing hypotheses (6) of niacin. Within each analyte, the adjusted P values for testing individual hypotheses maintained the same ranking as their corresponding raw P values; because these adjusted P values were never less than the P value for testing their composite UI hypotheses, retaining the null of hypotheses (6) coincided with retaining both nulls of hypotheses (4) and (5) at any given significance level. The proposed MTP thereby facilitates logical decision making. Chi (1998) . Organizing individual hypotheses according to decision rules, as in Fig. 5 , reduces the composite hypotheses in a biologically relevant and meaningful way. The two-stage MTP provides the statistical support for this strategy. Next, evaluate crop safety with respect to all 53 analytes in the example dataset. Appendix 2 executes the proposed MTP using the SAS DATA step and MULTTEST procedure. Table 4 The P values of these tests were unavailable. Seven analytes were considered as 'non-equivalence more likely than not' or 'equivalence more likely than not'. The guidance requested these analytes undergo further evaluation. Additionally, there were two analytes with zero estimated reference variability. They might also be subjected to further evaluation. However, a decision path for subsequent investigation remains elusive. The two-stage procedure led to a clear-cut conclusion: equivalence was significant at the 0·05 significance level in all 53 analytes. It was therefore unnecessary to conduct hazard characterization and exposure assessment. Tests for hypotheses (4) and (5) were both significant in 41 out of 53 analytes and 12 analytes had significance in only one of the two tests. For the 16 analytes where testing hypotheses (1) concluded significant difference, testing hypotheses (4) asserted practical equivalence between GMO and the non-GM counterpart in 13 analytes; testing hypotheses (5) declared GMO within the reference natural variation in 15 analytes. Regarding the 37 analytes with non-significant differences, three of them retained the null of hypotheses (4). It then comes as a reminder that non-significance in testing hypotheses (1) showed practical equivalence between GMO and the non-GM counterpart in testing hypotheses (4). Three were declared equivalent to references by testing hypotheses (5). When hypotheses (4) and (5) were integrated together into UI hypotheses, i.e. hypotheses (6), the GM crop was comparable with non-GM crops for all nine analytes. Following the current practice for testing IU hypotheses, global equivalence as defined in hypotheses (7) could be claimed at the 0·05 significance level based on the raw P values for testing hypotheses (6). One may then question the necessity of conducting multiplicity adjustment at the second stage. In fact, this simply demonstrates the aforementioned desirable property of consistency and should not be viewed as evidence against the proposed MTP. Recalling that 53 analyte-specific decisions were tested at the same time, a more relevant question to ask is whether the rate of erroneously asserting equivalence on one or more potentially hazardous analytes has been controlled. The second-stage adjustment was executed specifically to address this concern. It utilized the positive association between raw P values for testing hypotheses (6) and made adjustments from the second largest P value down to the smallest. To see this, consider the four analytes with the largest raw P values for testing hypotheses (6). The raw P values for niacin and phytic acid were 0·0418 and 0·0392, respectively. These two analytes would certainly undergo hazard characterization and exposure analysis at, say, the 0·01 significance level. For raffinose and vitamin E, multiplicity adjustment in the second stage raised their respective P values for testing hypotheses (6) from 0·0040 to 0·0120 and from 0·0027 to 0·0109. These two analytes would also be subjected to further evaluation at the 0·01 significance level. Without adjustment in the second stage, one would fail to mark raffinose and vitamin E as suspect analytes out of the 53 analytes simultaneously tested. The second stage of the proposed MTP is thus absolutely necessary for controlling the consumer's risk.
DISCUSSION
A CI describes the parameter on its own original scale and is preferred over hypothesis testing by many practitioners. The EFSA guidance requests CIs as a standard presentation for testing difference, equivalence and non-equivalence while accepting P values, if available, as supplementary results. Much of the emphasis on CIs originates from the fact that a conventional two-sided (1 − α) CI for μ 
Duality between CIs and P values should not be taken for granted when testing for multiple equivalences. One may mistakenly presume that switching (1 − α) to (1 − 2α) preserves duality between the conventional CI and the P value of TOST, since TOST utilizes endpoints of a conventional two-sided (1 − 2α) CI to assess equivalence. The most obvious counterexample for this misconception is to consider testing hypotheses (4) at δ 0 = 0. In this case, the null is surely true and the P value of TOST is always greater than α. But, a (1 − 2α) CI may not include the value of δ 0 = 0. It turns out that the CI compatible with the P value of TOST takes a more complex form ; case 2 of Bauer & Kieser 1996) . Regarding sequential testing, Hayter & Hsu (1994) show that the simultaneous confidence region (SCR) is determined by the hypothesis formulation together with practitioners' specific requirements. Guilbaud (2008 Guilbaud ( , 2012 has developed SCRs compatible with some basic MTPs. For rejected individual nulls, these SCRs might provide no extra information beyond that the individual alternatives are true. Concerned with this practical limitation, recommend sponsors of clinical efficacy studies to present individual CIs without connecting them to the results of multiple testing. As noted by Strassburger & Bretz (2008) , ad hoc updates to the confidence levels of individual CIs by their adjusted significance levels do not warrant a desired joint coverage. It is a question for future research how to construct a SCR compatible with the two-stage MTP and whether the SCR will be useful for GMO risk assessment.
This present work corrects multiplicity in GMO testing from field trials using the semiparametric SH adjustment in an attempt to avoid the low power of the non-parametric SSB and BH adjustments. Power for concluding equivalence could be increased further by parametric statistics. The simulation studies of have proven the generalized pivotal quantity method is helpful for testing hypotheses (5) alone. Extending this parametric method to the joint testing of hypotheses (4) and (5) entails greater technical complexity and will be a topic of future research. To this end, observe from Occurrence of such a pathological case is rare but probable since the non-GM counterpart might reside in the tail of the reference distribution and/or the EL might be too conservative. If one considers GMO as safe in this case, hypotheses for equivalence at a given endpoint can then be defined as: (12) will be better supported by the analyses of many real-world datasets.
The guidance on selecting comparators (EFSA 2011) suggests there may be more than one non-GM near-isogenic line suitable to serve as GMO's counterpart. Consider the general case that the study includes (J − 1) non-GM counterparts, J ⩾ 2. Individual hypotheses at a given endpoint comprise hypotheses (5) and:
The local UI hypotheses now become:
. . . P m ðJÞ as the ordered P values for the J individual hypotheses. Formula (9) ought to be replaced by: whereas Formula (10) still applies. Adjusting P values for individual hypotheses involves tedious calculation when J is large. Appendix 3 presents the formula at J = 3. The concept of substantial equivalence has long been criticized for its vague definition, which inadvertently permits progressive, unlimited expansion of the EL. The proposed MTP accommodates an integrative evaluation of safety from various resources while penalizing excessive comparisons with lower power. To minimize this penalty, sponsors are encouraged to choose the comparators in a parsimonious manner. In this regard, the statistical strategy of multiple testing harmoniously repositions the establishment of substantial equivalence onto scientifically sound and logically defensible ground. A GM crop under risk assessment may carry traits with insect resistance, herbicide tolerance, and/or enhanced nutrition. Its safety evaluation should obviously be conducted on a case-by-case basis depending on the genetic modification. In the past, the nature of GMO's traits has been considered after the statistical analyses were completed. For example, Brink et al. (2014) submitted all key nutrients of a GM soy to the evaluation process depicted in Fig. 1 and then reviewed the observed changes in fatty acid compositions. Because the crop was bioengineered to have a high content of oleic acid, it is paradoxical to evaluate efficacy and safety endpoints using the same formulation of hypotheses. Their multiplicity adjustment to these tests has little meaning, since neither the consumer's nor the sponsors' risk was controlled. A sensible strategy is to pre-classify endpoints into three groups according to the traits owned by the GMO. Endpoints with no anticipated change form one group and their safety is established via multiple equivalence testing. Non-significant endpoints will proceed to hazard characterization and exposure assessment. Endpoints with expected, but unintended, change belong to the second group. They directly enter hazard characterization and exposure assessment. Endpoints in the third group are intended targets of genetic modification and are excluded from the risk assessment. This strategy satisfies the special need for prudent evaluation of nutritionally enriched GMOs. Also note that the power for concluding equivalence is increased as a result of fewer endpoints under multiplicity adjustment.
The problem of testing multiple hypotheses is deeply rooted in crop safety evaluation. A viable solution hinges on a powerful testing strategy that is easy to apply and convey. The present work translates the objectives and decision rules for establishing substantial equivalence into families of explicitly defined hypotheses. This novel interpretation leads to the creation of a two-stage semi-parametric MTP tailored specifically to GMO testing from field trials. By exploiting the positive correlations among comparisons within and across endpoints, this new procedure reduces the conservativeness of multiplicity adjustment. Its practical utility is shown in a real-world example. Literature on multiple testing has dealt mainly with clinical studies. One might argue that multiplicity adjustment is too stringent for GMO studies. Nonetheless, if statistical inference is employed to assure the reliability of crop safety evaluation, there is no reason not to pursue its full extent with regard to restricting the risk of at least one false conclusion, i.e. the FWER. Sponsors of GMOs have not been required to disclose the exact decision rules in the planning phase of their studies. It is only after the completion of all statistical analyses that biological judgments enter the evaluation. This ignores the pre-eminent need to control the consumer's risk and undermines the integrity of the entire assessment. Multiple testing emphasizes the importance of prespecified decision rules so as to control the FWER. Provided that these decision rules have great biological and/or practical meaning, there is no need for post hoc 'tweaking' to the statistical results. Sponsors benefit from scientific diligence in decision making, too. The recommendations above -including parametric testing, careful selection of non-GM counterparts and exclusion of efficacy endpoints -all raise sponsors' chances of concluding equivalence. Statistical strategies for multiple testing therefore pave the way for a transparent, disciplined scheme to assess GMO safety.
APPENDIX 1
Basic procedures and fundamental principles for multiple testing Multiplicity poses different challenges depending on whether the composite hypotheses are IU or UI. With no adjustment, it is more difficult to conclude 'each-and-every' than to reject an individual null.
Testing IU hypotheses is burdened by this power deficiency and a well-accepted solution has yet to be discovered. When testing UI hypotheses, the opposite problem occurs in that concluding 'at-least-one' without adjustment inflates the FWER. Consider the general setting where separate testing of N individual hypotheses generates ordered P values of {P (1) , …, P (N) }, P (1) ⩽ … ⩽ P (N) . The SSB procedure uses the robust Bonferroni inequality to conservatively control the FWER. Its P value for testing the global UI hypotheses is P ¼ NP ð1Þ
The SSB-adjusted P values of individual tests arẽ P ðnÞ ¼ NP ðnÞ ; n ¼ 1; :::; N Without further mention, adjusted P values >1 will be immediately truncated to 1. Note that inference on individual hypotheses is made without referring to each other. Power of this procedure is infamously low for large N and/or correlated testing outcomes.
Multiplicity adjustment under a UI context attends to an underlying closed family of hypotheses where any UI combination of its members also belongs to the family. For example, hypotheses (4-6) at a given endpoint form a closed family whereas the closure induced by
members in the form of hypotheses (8). To prevent a MTP from generating conflicting results, Gabriel (1969) introduces the logical constraint of coherence, i.e. if a composite null is retained, all its component nulls should be retained. The closure principle serves as the general method for constructing coherent MTPs (Marcus et al. 1976; Sonnemann 1982; Grechanovsky & Hochberg 1999) . It requires that any null in the closed family is rejected if and only if all the related composite nulls have been rejected. Regarding the closed family of hypotheses (4-6) at a given endpoint, coherence means that if the null of hypotheses (6) is retained, the nulls for hypotheses (4) and (5) should be retained and the closure principle calls for a MTP whose P values for testing hypotheses (4) and (5) are no less than that for testing hypotheses (6). The BH and the SH procedures are two classical coherent MTPs created under the closure principle. The BH procedure computes the raw P values for testing all composite hypotheses on the basis of the Bonferroni inequality (Holm 1979) . Westfall et al. (1999) provide the BH-adjusted P values for testing the N individual hypotheses as The BH procedure has close ties with the SSB procedure: (i) its P value for testing the global UI hypotheses is also NP (1) ; (ii) both procedures are non-parametric in the sense that there is no restriction on the relationship among individual tests. The SH procedures computes the P value for testing the global UI hypotheses on the basis of Simes (1986) It applies the closure principle to adjust for multiplicity in testing individual hypotheses (Hochberg 1988 ). According to Westfall et al. (1999) , the SH-adjusted P values for testing the Nindividual hypotheses are: Simes (1986) shows that Formula (A1) leads to a FWER at the nominal level when the test statistics of individual hypotheses are continuous and independent. For a general class of positively dependent test statistics, Formula (A1) conservatively preserves the FWER (Sarkar 1998 (Sarkar , 2008 Sarkar & Chang 1997) . The SH procedure restrains the FWER by assuming positive dependence and is semiparametric in this regard. Interestingly, application of the closure principle in the aforementioned simple cases generates MTPs that sequentially adjust for multiplicity in an order determined by the data: the BH procedure starts from the smallest P value P (1) and moves up step-by-step to P (N) ; the SH procedure starts from the largest P value P (N) and works its way down to P (1) . The BH and SH procedures evidently have better power to reject an individual null than the SSB procedure. Westfall & Kristen (2001) show that maximum power can be achieved by sequentially testing individual hypotheses according to their logical ranking. Goeman & Solari (2010) later summarize these findings into the sequential rejection principle, i.e. a MTP should arrange individual hypotheses in certain orders and reject them in a stepwise manner. A predetermined logical order is ideal but rarely available except in some dose-response studies with perceived monotonicity of treatment effects as well as in studies with primary and secondary objectives. Sequential MTPs on the basis of a data-driven order, such as the BH and SH procedures, have gained popularity, especially since they are easy to execute and interpret.
The partition principle further improves power of MTPs for a closed family. It dissects the entire parameter space into small pieces in an effort to trim the space for relevant inferences (Hsu & Berger 1999; Finner & Strassburger 2002; Liu & Hsu 2009 ). Execution of this principle requires a high level of technical sophistication and becomes more practical when individual hypotheses are naturally ordered. ; run; /*Stage 1: Compute P values for Hypo. (6) */ data summary_statistics; set summary_statistics; pvalue_Hypo1 = 2*cdf('T',-abs(log(TCratio)/seTC),dfTC); pvalue_Hypo4 = max(cdf('T',(log(TCratio)-log(1·20))/seTC,dfTC), 1-cdf('T',(log(TCratio) + log(1·20))/seTC,dfTC)); pvalue_Hypo6 = min(2*min(pvalue_Hypo4, pvalue_Hypo5),max(pvalue_Hypo4, pvalue_Hypo5)); raw_p = pvalue_Hypo6; run; /*Stage2: Adjust P values for Hypo. (6) */ proc multtest hochberg inpvalues = summary_statistics out = set1; id analyte; run; /*Stage2: Adjust P values for Hypo. (4) and (5): hoc_p is the adjusted P value for Hypo (6).*/ proc sort data = summary_statistics;by analyte; proc sort data = set1;by analyte; data pvalue; format pvalue_Hypo1 pvalue.; merge summary_statistics set1(keep = analyte hoc_p); by analyte; pvalue_Hypo4_adj = max(pvalue_Hypo4,hoc_p); pvalue_Hypo5_adj = max(pvalue_Hypo5,hoc_p); run;
APPENDIX 3
Adjusted P values for testing three individual hypotheses per endpoint By the closure principle and the SH adjustment, Formula (11) at J = 3 should be updated tõ Grp4 Zinc  0·978  0·02495  42·5  0·0002  I  Grp5 Folic acid  1·138  0·12096  44·1  0  I  Grp5 Niacin  0·872  0·0216  41·7  0·6652  III  Grp5 Vitamin B1  1·023  0·02433  43·3  0  I  Grp5 Vitamin B2  0·938  0·03784  49  0·0006  I  Grp5 Vitamin B6  0·997  0·0229  41·6  0·2948  II  Grp5 Vitamin E  0·953  0·04217  42·5  0·4432  II  Grp6 Ferulic acid  0·87  0·04008  41·8  0  I  Grp6 Phytic acid  0·919  0·07949  53·2  0·0196  V  Grp6 Raffinose  1·036  0·07232  49·1  0·002  I  Grp6 p-coumaric acid  0·957  0·04565  42·1  0  I 
